Physician profile
Christopher H Rush
NPI 1023003589
$11,724.65
in general payments reported to CMS, 2019-2025
54 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,108 · 2020: $1,948 · 2021: $2,268 · 2022: $1,178 · 2023: $1,215 · 2024: $1,395 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,107 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,106.92 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,445.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $990.11 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $927.88 | 2019-2025 | Uplizna, Repatha, Evenity |
| Lilly USA, LLC | $900.99 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $864.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $763.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $761.01 | 2019-2025 | Jardiance |
| Abbvie INC. | $670.05 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Janssen Pharmaceuticals, INC | $581.70 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $302.58 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $290.31 | 2019-2023 | Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $255.84 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $242.38 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $228.69 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $167.36 | 2019-2024 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.